Every year, 700,000 people are thought to die from antimicrobial-resistant (AMR) infections globally. Without effective measures to address this issue, it is projected that the annual death toll will rise to up to 10 million by 2050. In Japan, the AMR Clinical Reference Center at the National Center for Global Health and Medicine estimates that there were approximately 8,000 deaths in 2017 due to bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) and fluoroquinolone-resistant Escherichiacoli (FQREC), two of the most common antimicrobial-resistant bacteria.
Antimicrobial drugs play an important role in modern medicine and have contributed to curing infections and improving patient prognosis. At the same time, AMR has emerged as a serious problem that threatens the future of the country’s health care system, and robust policies are needed to address this growing threat.